Treatment Information

Imagine a scenario where basic activities such as walking, eating, or even breathing become nearly impossible to achieve without assistance. This is the reality for many individuals living with Spinal Muscular Atrophy (SMA), a rare neuromuscular disorder. But the advent of recent treatments, has brought newfound hope to those affected by SMA.

If you desire to seek treatment, it is mandatory to fulfil the requirements regarding residency and any other stipulations that determine your entitlement to specialised NHS treatment. The regulations that oversee this are intricate, so if you’re unsure about your privileges, don’t hesitate to consult with your GP or the Treatment Centre you plan to visit.

Each specific treatment also comes with its own set of eligibility prerequisites.

On this website, you’ll find detailed discussions about each treatment, including in-depth aspects, FAQs about access agreements, and the outcomes of clinical trials.

Click below to find out more information about available treatments.

Zolgensma

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more